Literature DB >> 30917949

A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.

Eli L Diamond1, Anne S Reiner2, Justin J Buthorn1, Elyse Shuk3, Allison J Applebaum3, David M Hyman4, Omar Abdel-Wahab4, Raajit Rampal4, Filip Janku5, Kathleen Brewer6, Jean Campbell6, Jun J Mao4, Thomas M Atkinson3, Katherine S Panageas2.   

Abstract

Erdheim-Chester disease (ECD) is an ultra-rare hematologic neoplasm characterized by somatic mutations of the MAPK pathway and by accumulation of lesional histiocytes within tissues. Clinical phenotypes and sites of disease involvement are heterogenous in ECD, and no tool exists for systematic and comprehensive assessment of ECD symptomatology. We describe a collaborative effort among ECD specialists, patient-reported outcome (PRO) methodologists, and ECD patients to develop the Erdheim-Chester Disease Symptom Scale (ECD-SS): a symptom inventory for clinical ECD care and evaluation of ECD therapies. Methodologically rigorous focus groups led to the identification of 63 ECD symptoms in 6 categories, incorporated into the ECD-SS with respect to both severity and frequency. Among 50 ECD patients participating in a prospective registry study completing the ECD-SS, 46 (92%) reported neurological/psychological symptoms, 29 (58%) reported pain, and at least one-half reported mood symptoms, memory problems, or fatigue. Symptoms were highly frequent or almost constant regardless of their severity. The ECD-SS is a rigorously developed, patient-centered tool that demonstrates the wide and previously unappreciated burden of symptomatology experienced by ECD patients. Further studies will refine the symptom inventory and define its psychometric properties and role in clinical care and investigation in the context of ECD.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 30917949      PMCID: PMC6457219          DOI: 10.1182/bloodadvances.2018030502

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  14 in total

1.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-10       Impact factor: 5.725

2.  Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: towards a new therapeutic approach.

Authors:  Achille Aouba; Benjamin Terrier; Viorel Vasiliu; Sophie Candon; Nicole Brousse; Bruno Varet; Olivier Hermine
Journal:  Haematologica       Date:  2006-12       Impact factor: 9.941

Review 3.  Histiocytoses: emerging neoplasia behind inflammation.

Authors:  Julien Haroche; Fleur Cohen-Aubart; Barret J Rollins; Jean Donadieu; Frédéric Charlotte; Ahmed Idbaih; Augusto Vaglio; Omar Abdel-Wahab; Jean-François Emile; Zahir Amoura
Journal:  Lancet Oncol       Date:  2017-02       Impact factor: 41.316

4.  Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab.

Authors:  Lorenzo Dagna; Angelo Corti; Silvia Langheim; Barbara Guglielmi; Francesco De Cobelli; Claudio Doglioni; Gabriele Fragasso; Maria Grazia Sabbadini; Marina Ferrarini
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

5.  Patient-Reported Outcomes - Harnessing Patients' Voices to Improve Clinical Care.

Authors:  Ethan Basch
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

6.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

7.  Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients.

Authors:  Laurent Arnaud; Guy Gorochov; Frédéric Charlotte; Virginie Lvovschi; Christophe Parizot; Martin Larsen; Pascale Ghillani-Dalbin; Baptiste Hervier; Jean-Emmanuel Kahn; Claire Deback; Lucile Musset; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2011-01-04       Impact factor: 22.113

Review 8.  What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials.

Authors:  Grigorios Kotronoulas; Nora Kearney; Roma Maguire; Alison Harrow; David Di Domenico; Suzanne Croy; Stephen MacGillivray
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

9.  Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.

Authors:  Akira Morimoto; Yukiko Oh; Sachie Nakamura; Yoko Shioda; Tomomi Hayase; Toshihiko Imamura; Kazuko Kudo; Shinsaku Imashuku
Journal:  Cytokine       Date:  2017-06-02       Impact factor: 3.861

Review 10.  Erdheim-Chester disease: characteristics and management.

Authors:  Javier Munoz; Filip Janku; Philip R Cohen; Razelle Kurzrock
Journal:  Mayo Clin Proc       Date:  2014-05-09       Impact factor: 7.616

View more
  9 in total

Review 1.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

Review 2.  Erdheim-Chester Disease: a Concise Review.

Authors:  Matthias Papo; Jean-François Emile; Thiago Trovati Maciel; Pierre Bay; Alistair Baber; Olivier Hermine; Zahir Amoura; Julien Haroche
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

Review 3.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

4.  The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease.

Authors:  Allison J Applebaum; Laura C Polacek; Leah Walsh; Anne S Reiner; Kathleen Lynch; Stephanie Benvengo; Justin Buthorn; Thomas M Atkinson; Jun J Mao; Katherine S Panageas; Eli L Diamond
Journal:  Leuk Lymphoma       Date:  2020-02-24

Review 5.  Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.

Authors:  Hind Abdin Salama; Abdul Rahman Jazieh; Ayman Yahya Alhejazi; Ahmed Absi; Saeed Alshieban; Mohsen Alzahrani; Ahmed Alaskar; Giamal Gmati; Moussab Damlaj; Khadega A Abuelgasim; Abdulrahman Alghamdi; Bader Alahmari; Areej Almugairi; Hazza Alzahrani; Ali Bazarbachi; M O H Musa; Gaurav Goyal
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-08-18

6.  Psychological features of adult patients with langerhans cell histiocytosis.

Authors:  Emmanuelle Bugnet; Nishant Gupta; Gwenaël Lorillon; Sayena Arbabzadeh-Bouchez; Cédric Lemogne; Sylvie Chevret; Abdellatif Tazi
Journal:  PLoS One       Date:  2021-02-12       Impact factor: 3.240

7.  Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease.

Authors:  Eleonora Lauricella; Antonio d'Amati; Giuseppe Ingravallo; Maurizio Foresio; Domenico Ribatti; Marina de Tommaso; Mauro Cives; Francesco Girolamo
Journal:  Cerebellum Ataxias       Date:  2021-01-06

8.  Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAFV600E -Mutated Erdheim-Chester Disease: A Case Report.

Authors:  Jérôme Razanamahery; Maroua Abdallahoui; Guillaume Chabridon; Agnès Fromont; Georges Tarris; Ahmed Idbaih; Pierre Olivier Comby; Francois Godard; Julien Haroche; Sylvain Audia; Bernard Bonnotte
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

9.  Challenges and positive impact of rare cancer caregiving: A mixed-methods study of caregivers of patients with Erdheim-Chester disease and other histiocytic neoplasms.

Authors:  Hannah-Rose Mitchell; Allison J Applebaum; Kathleen A Lynch; Anne S Reiner; Thomas M Atkinson; Justin J Buthorn; Allison S Sigler; Dana Bossert; Kathleen Brewer; Jessica Corkran; Deanna Fournier; Katherine S Panageas; Eli L Diamond
Journal:  EClinicalMedicine       Date:  2022-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.